{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:17:27Z","timestamp":1793812647119,"version":"4.6.1"},"reference-count":136,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Despite increasing worldwide incidence of Parkinson\u2019s disease, the therapy\nis still suboptimal due to the diversified clinical manifestations, lack of sufficient treatment, the poor\nadherence in advanced patients, and varied response. Proper intake of medications regarding food\nand managing drug-food interactions may optimize Parkinson\u2019s disease treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>We investigated potential effects that food, beverages, and dietary supplements may\nhave on the pharmacokinetics and pharmacodynamics of drugs used by parkinsonian patients; identified\nthe most probable interactions; and shaped recommendations for the optimal intake of drugs\nregarding food.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a systematic review in adherence to PRISMA guidelines, and included a\ntotal of 81 studies in the qualitative synthesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and Conclusions:<\/jats:title>\n                    <jats:p>We found evidence for levodopa positive interaction with coffee, fiber and\nvitamin C, as well as for the potential beneficial impact of low-fat and protein redistribution diet.\nContrastingly, high-protein diet and ferrous sulfate supplements can negatively affect levodopa\npharmacokinetics and effectiveness. For other drugs, the data of food impact are scarce. Based on\nthe available limited evidence, all dopamine agonists (bromocriptine, cabergoline, ropinirole), tolcapone,\nrasagiline, selegiline in tablets, safinamide, amantadine and pimavanserin can be taken with\nor without a meal. Opicapone and orally disintegrating selegiline tablets should be administered on\nan empty stomach. Of monoamine oxidase B inhibitors, safinamide is the least susceptible for interaction\nwith the tyramine-rich food, whereas selegiline and rasagiline may lose selectivity to monoamine\noxidase B when administered in supratherapeutic doses. The level of presented evidence is\nlow due to the poor studies design, their insufficient actuality, and missing data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1570159x19666211116142806","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T23:43:25Z","timestamp":1637106205000},"page":"1427-1447","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["How to Optimize the Effectiveness and Safety of Parkinson\u2019s Disease\nTherapy? \u2013 A Systematic Review of Drugs Interactions with Food and Dietary\nSupplements"],"prefix":"10.2174","volume":"20","author":[{"given":"Wiesner","family":"Agnieszka","sequence":"first","affiliation":[{"name":"Department of Food Chemistry and Nutrition, Faculty of Pharmacy, Jagiellonian University Medical College, 9\nMedyczna Str, 30-688 Krak\u00f3w, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pa\u015bko","family":"Pawe\u0142","sequence":"additional","affiliation":[{"name":"Department of Food Chemistry and Nutrition, Faculty of Pharmacy, Jagiellonian University Medical College, 9\nMedyczna Str, 30-688 Krak\u00f3w, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kujawska","family":"Ma\u0142gorzata","sequence":"additional","affiliation":[{"name":"Department of Toxicology, Poznan University of Medical Sciences, 30 Dojazd\nStr., 60-631 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/978-94-007-5416-4_16","volume":"65","author":"Mhyre T.R.","year":"2012","unstructured":"Mhyre T.R.; Boyd J.T.; Hamill R.W.; Maguire-Zeiss K.A.; Parkinson\u2019s disease. Subcell Biochem 2012,65,389-455","journal-title":"Subcell Biochem"},{"key":"ref=2","unstructured":"Up To Date: Clinical manifestations of Parkinson disease. Available from:  (Accessed Mar 16, 2021)."},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.parkreldis.2011.11.006","volume":"18","author":"Kalf J.G.","year":"2012","unstructured":"Kalf J.G.; de Swart B.J.; Bloem B.R.; Munneke M.; Prevalence of oropharyngeal dysphagia in Parkinson\u2019s disease: a meta-analysis. Parkinsonism Relat Disord 2012,18(4),311-315","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s00455-016-9695-9","volume":"31","author":"Takizawa C.","year":"2016","unstructured":"Takizawa C.; Gemmell E.; Kenworthy J.; Speyer R.; A systematic review of the prevalence of oropharyngeal dysphagia in stroke, Par-kinson\u2019s disease, Alzheimer\u2019s disease, head injury, and pneumonia. Dysphagia 2016,31(3),434-441","journal-title":"Dysphagia"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"Hoehn M.M.","year":"1967","unstructured":"Hoehn M.M.; Yahr M.D.; Parkinsonism: onset, progression and mortality. Neurology 1967,17(5),427-442","journal-title":"Neurology"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","year":"2018","unstructured":"Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018,17(11),939-953","journal-title":"Lancet Neurol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","volume":"75","author":"Dorsey E.R.","year":"2018","unstructured":"Dorsey E.R.; Bloem B.R.; The parkinson pandemic-A call to action. JAMA Neurol 2018,75(1),9-10","journal-title":"JAMA Neurol"},{"key":"ref=8","unstructured":"National Institute for Health and Care Excellence: Parkinson\u2019s disease in adults - NICE guidelines. Available from:  (Accessed Mar 16, 2021)."},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"E989","DOI":"10.1503\/cmaj.181504","volume":"191","author":"Grimes D.","year":"2019","unstructured":"Grimes D.; Fitzpatrick M.; Gordon J.; Miyasaki J.; Fon E.A.; Schlossmacher M.; Suchowersky O.; Rajput A.; Lafontaine A.L.; Mes-tre T.; Appel-Cresswell S.; Kalia S.K.; Schoffer K.; Zurowski M.; Postuma R.B.; Udow S.; Fox S.; Barbeau P.; Hutton B.; Canadian guideline for Parkinson disease. CMAJ 2019,191(36),E989-E1004","journal-title":"CMAJ"},{"key":"ref=10","unstructured":"UpToDate Management of nonmotor symptoms in Parkinson disease Available from:  (Accessed Mar 16, 2021).","journal-title":"Management of nonmotor symptoms in Parkinson disease"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"e10962","DOI":"10.1097\/MD.0000000000010962","volume":"97","author":"Straka I.","year":"2018","unstructured":"Straka I.; Min&#xE1;r M.; Ga&#x17E;ov&#xE1; A.; Valkovi&#x10D; P.; Kyselovi&#x10D; J. Clinical aspects of adherence to pharmacotherapy in Parkinson disease: A PRISMA-compliant systematic review. Medicine (Baltimore) 2018,97(23),e10962","journal-title":"Medicine (Baltimore)"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"093146","DOI":"10.1063\/5.0014800","volume":"30","author":"V&#xE9;ronneau-Veilleux F.","year":"2020","unstructured":"V&#xE9;ronneau-Veilleux F.; Ursino M.; Robaey P.; L&#xE9;vesque D.; Nekka F.; Nonlinear pharmacodynamics of levodopa through Parkinson\u2019s disease progression. Chaos 2020,30(9),093146","journal-title":"Chaos"},{"key":"ref=13","first-page":"107","year":"2020","unstructured":"In: Encyclopedia of Biomedical Gerontology 2020,107-114","journal-title":"In: Encyclopedia of Biomedical Gerontology"},{"key":"ref=14","unstructured":"UpToDate Medical management of motor fluctuations and dyskinesia in Parkinson disease Available from:  (Accessed Apr 30, 2021).","journal-title":"Medical management of motor fluctuations and dyskinesia in Parkinson disease"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4155\/tde.15.96","volume":"7","author":"Jimenez-Shahed J.","year":"2016","unstructured":"Jimenez-Shahed J.; A review of current and novel levodopa formulations for the treatment of Parkinson\u2019s disease. Ther Deliv 2016,7(3),179-191","journal-title":"Ther Deliv"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40263-016-0336-5","volume":"30","author":"Wirdefeldt K.","year":"2016","unstructured":"Wirdefeldt K.; Odin P.; Nyholm D.; Levodopa-carbidopa intestinal gel in patients with Parkinson\u2019s disease: A systematic review. CNS Drugs 2016,30(5),381-404","journal-title":"CNS Drugs"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1056\/NEJM198402233100802","volume":"310","author":"Nutt J.G.","year":"1984","unstructured":"Nutt J.G.; Woodward W.R.; Hammerstad J.P.; Carter J.H.; Anderson J.L.; The &#x201C;on-off&#x201D; phenomenon in Parkinson\u2019s disease. Relation to levodopa absorption and transport. N Engl J Med 1984,310(8),483-488","journal-title":"N Engl J Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/00002826-198712000-00004","volume":"10","author":"Baruzzi A.","year":"1987","unstructured":"Baruzzi A.; Contin M.; Riva R.; Procaccianti G.; Albani F.; Tonello C.; Zoni E.; Martinelli P.; Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987,10(6),527-537","journal-title":"Clin Neuropharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000116172","volume":"27","author":"Malcolm S.L.","year":"1987","unstructured":"Malcolm S.L.; Allen J.G.; Bird H.; Quinn N.P.; Marion M.H.; Marsden C.D.; O\u2019Leary C.G.; Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers. Eur Neurol 1987,27(Suppl. 1),28-35","journal-title":"Eur Neurol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00002826-199108000-00003","volume":"14","author":"Wilding I.R.","year":"1991","unstructured":"Wilding I.R.; Hardy J.G.; Davis S.S.; Melia C.D.; Evans D.F.; Short A.H.; Sparrow R.A.; Yeh K.C.; Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR). Clin Neuropharmacol 1991,14(4),305-321","journal-title":"Clin Neuropharmacol"},{"key":"ref=21","unstructured":"Madopar (Roche) Product characteristics. Available from:  (accessed May 13, 2021)."},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0303-8467(93)90126-2","volume":"95","author":"Roos R.A.","year":"1993","unstructured":"Roos R.A.; Tijssen M.A.; van der Velde E.A.; Breimer D.D.; The influence of a standard meal on Sinemet CR absorption in patients with Parkinson\u2019s disease. Clin Neurol Neurosurg 1993,95(3),215-219","journal-title":"Clin Neurol Neurosurg"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s002280050464","volume":"54","author":"Contin M.","year":"1998","unstructured":"Contin M.; Riva R.; Martinelli P.; Albani F.; Baruzzi A.; Effect of meal timing on the kinetic-dynamic profile of levodopa\/carbidopa controlled release [corrected] in parkinsonian patients. Eur J Clin Pharmacol 1998,54(4),303-308","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0939-6411(02)00124-8","volume":"55","author":"Crevoisier C.","year":"2003","unstructured":"Crevoisier C.; Zerr P.; Calvi-Gries F.; Nilsen T.; Effects of food on the pharmacokinetics of levodopa in a dual-release formulation. Eur J Pharm Biopharm 2003,55(1),71-76","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/WNF.0000000000000126","volume":"39","author":"Yao H.M.","year":"2016","unstructured":"Yao H.M.; Hsu A.; Gupta S.; Modi N.B.; Clinical pharmacokinetics of IPX066: Evaluation of dose proportionality and effect of food in healthy volunteers. Clin Neuropharmacol 2016,39(1),10-17","journal-title":"Clin Neuropharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.parkreldis.2021.09.001","volume":"91","author":"Miyaue N.","year":"2021","unstructured":"Miyaue N.; Hosokawa Y.; Yoshida A.; Yamanishi Y.; Tada S.; Ando R.; Yabe H.; Nagai M.; Fasting state is one of the factors associ-ated with plasma levodopa fluctuations during levodopa\u2012carbidopa intestinal gel treatment. Parkinsonism Relat Disord 2021,91,55-58","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/archneur.1987.00520220009006","volume":"44","author":"Juncos J.L.","year":"1987","unstructured":"Juncos J.L.; Fabbrini G.; Mouradian M.M.; Serrati C.; Chase T.N.; Dietary influences on the antiparkinsonian response to levodopa. Arch Neurol 1987,44(10),1003-1005","journal-title":"Arch Neurol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1136\/jnnp.52.9.1063","volume":"52","author":"Frankel J.P.","year":"1989","unstructured":"Frankel J.P.; Kempster P.A.; Bovingdon M.; Webster R.; Lees A.J.; Stern G.M.; The effects of oral protein on the absorption of intra-duodenal levodopa and motor performance. J Neurol Neurosurg Psychiatry 1989,52(9),1063-1067","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1212\/WNL.41.8.1295","volume":"41","author":"Berry E.M.","year":"1991","unstructured":"Berry E.M.; Growdon J.H.; Wurtman J.J.; Caballero B.; Wurtman R.J.; A balanced carbohydrate: protein diet in the management of Par-kinson\u2019s disease. Neurology 1991,41(8),1295-1297","journal-title":"Neurology"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1056\/NEJM197501232920404","volume":"292","author":"Mena I.","year":"1975","unstructured":"Mena I.; Cotzias G.C.; Protein intake and treatment of Parkinson\u2019s disease with levodopa. N Engl J Med 1975,292(4),181-184","journal-title":"N Engl J Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1001\/archneur.1987.00520150026014","volume":"44","author":"Pincus J.H.","year":"1987","unstructured":"Pincus J.H.; Barry K.; Influence of dietary protein on motor fluctuations in Parkinson\u2019s disease. Arch Neurol 1987,44(3),270-272","journal-title":"Arch Neurol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/archneur.1987.00520220012007","volume":"44","author":"Pincus J.H.","year":"1987","unstructured":"Pincus J.H.; Barry K.M.; Plasma levels of amino acids correlate with motor fluctuations in parkinsonism. Arch Neurol 1987,44(10),1006-1009","journal-title":"Arch Neurol"},{"key":"ref=33","first-page":"133","volume":"60","author":"Pincus J.H.","year":"1987","unstructured":"Pincus J.H.; Barry K.M.; Dietary method for reducing fluctuations in Parkinson\u2019s disease. Yale J Biol Med 1987,60(2),133-137","journal-title":"Yale J Biol Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.parkreldis.2003.10.004","volume":"10","author":"Simon N.","year":"2004","unstructured":"Simon N.; Gantcheva R.; Bruguerolle B.; Viallet F.; The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkin-son\u2019s disease. Parkinsonism Relat Disord 2004,10(3),137-142","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1365-2125.1991.tb05555.x","volume":"31","author":"Robertson D.R.","year":"1991","unstructured":"Robertson D.R.; Higginson I.; Macklin B.S.; Renwick A.G.; Waller D.G.; George C.F.; The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. Br J Clin Pharmacol 1991,31(4),413-417","journal-title":"Br J Clin Pharmacol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0002-8223(21)08917-3","volume":"62","author":"Gillespie N.G.","year":"1973","unstructured":"Gillespie N.G.; Mena I.; Cotzias G.C.; Bell M.A.; Diets affecting treatment of parkinsonism with levodopa. J Am Diet Assoc 1973,62(5),525-528","journal-title":"J Am Diet Assoc"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/WNL.38.8.1245","volume":"38","author":"Eriksson T.","year":"1988","unstructured":"Eriksson T.; Gran&#xE9;rus A.K.; Linde A.; Carlsson A.; \u2018On-off\u2019 phenomenon in Parkinson\u2019s disease: relationship between dopa and other large neutral amino acids in plasma. Neurology 1988,38(8),1245-1248","journal-title":"Neurology"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1212\/WNL.39.4.549","volume":"39","author":"Tsui J.K.","year":"1989","unstructured":"Tsui J.K.; Ross S.; Poulin K.; Douglas J.; Postnikoff D.; Calne S.; Woodward W.; Calne D.B.; The effect of dietary protein on the effi-cacy of L-dopa: a double-blind study. Neurology 1989,39(4),549-552","journal-title":"Neurology"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1212\/WNL.39.4.552","volume":"39","author":"Carter J.H.","year":"1989","unstructured":"Carter J.H.; Nutt J.G.; Woodward W.R.; Hatcher L.F.; Trotman T.L.; Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson\u2019s disease. Neurology 1989,39(4),552-556","journal-title":"Neurology"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1002\/mds.21003","volume":"21","author":"Barichella M.","year":"2006","unstructured":"Barichella M.; Marczewska A.; De Notaris R.; Vairo A.; Baldo C.; Mauri A.; Savardi C.; Pezzoli G.; Special low-protein foods amelio-rate postprandial off in patients with advanced Parkinson\u2019s disease. Mov Disord 2006,21(10),1682-1687","journal-title":"Mov Disord"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/10284150701414046","volume":"10","author":"Barichella M.","year":"2007","unstructured":"Barichella M.; Savardi C.; Mauri A.; Marczewska A.; Vairo A.; Baldo C.; Massarotto A.; Cordara S.E.; Pezzoli G.; Diet with LPP for renal patients increases daily energy expenditure and improves motor function in parkinsonian patients with motor fluctuations. Nutr Neurosci 2007,10(3-4),129-135","journal-title":"Nutr Neurosci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3389\/fnagi.2017.00206","volume":"9","author":"Wang L.","year":"2017","unstructured":"Wang L.; Xiong N.; Huang J.; Guo S.; Liu L.; Han C.; Zhang G.; Jiang H.; Ma K.; Xia Y.; Xu X.; Li J.; Liu J.Y.; Wang T.; Protein-restricted diets for ameliorating motor fluctuations in Parkinson\u2019s disease. Front Aging Neurosci 2017,9,206","journal-title":"Front Aging Neurosci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1212\/WNL.38.3.481","volume":"38","author":"Pincus J.H.","year":"1988","unstructured":"Pincus J.H.; Barry K.; Protein redistribution diet restores motor function in patients with dopa-resistant &#x201C;off&#x201D; periods. Neurology 1988,38(3),481-483","journal-title":"Neurology"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1212\/WNL.38.7.1026","volume":"38","author":"Riley D.","year":"1988","unstructured":"Riley D.; Lang A.E.; Practical application of a low-protein diet for Parkinson\u2019s disease. Neurology 1988,38(7),1026-1031","journal-title":"Neurology"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000116649","volume":"31","author":"Bracco F.","year":"1991","unstructured":"Bracco F.; Malesani R.; Saladini M.; Battistin L.; Protein redistribution diet and antiparkinsonian response to levodopa. Eur Neurol 1991,31(2),68-71","journal-title":"Eur Neurol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/archneur.1992.00530260049018","volume":"49","author":"Karstaedt P.J.","year":"1992","unstructured":"Karstaedt P.J.; Pincus J.H.; Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol 1992,49(2),149-151","journal-title":"Arch Neurol"},{"key":"ref=47","first-page":"189","volume":"91","author":"Gim&#xE9;nez-Rold&#xE1;n S.","year":"1991","unstructured":"Gim&#xE9;nez-Rold&#xE1;n S.; Mateo D.; Predicting beneficial response to a protein-redistribution diet in fluctuating Parkinson\u2019s disease. Acta Neurol Belg 1991,91(4),189-200","journal-title":"Acta Neurol Belg"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40734-016-0036-9","volume":"3","author":"Virmani T.","year":"2016","unstructured":"Virmani T.; Tazan S.; Mazzoni P.; Ford B.; Greene P.E.; Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson\u2019s disease. J Clin Mov Disord 2016,3,8","journal-title":"J Clin Mov Disord"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/mds.23226","volume":"25","author":"Cereda E.","year":"2010","unstructured":"Cereda E.; Barichella M.; Pedrolli C.; Pezzoli G.; Low-protein and protein-redistribution diets for Parkinson\u2019s disease patients with mo-tor fluctuations: a systematic review. Mov Disord 2010,25(13),2021-2034","journal-title":"Mov Disord"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/mds.1166","volume":"16","author":"Gordon P.H.","year":"2001","unstructured":"Gordon P.H.; Frucht S.J.; Neuroleptic malignant syndrome in advanced Parkinson\u2019s disease. Mov Disord 2001,16(5),960-962","journal-title":"Mov Disord"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1345\/aph.1K450","volume":"42","author":"Cooper M.K.","year":"2008","unstructured":"Cooper M.K.; Brock D.G.; McDaniel C.M.; Interaction between levodopa and enteral nutrition. Ann Pharmacother 2008,42(3),439-442","journal-title":"Ann Pharmacother"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1345\/aph.1P242","volume":"44","author":"Bonnici A.","year":"2010","unstructured":"Bonnici A.; Ruiner C.E.; St-Laurent L.; Hornstein D.; An interaction between levodopa and enteral nutrition resulting in neuroleptic ma-lignant-like syndrome and prolonged ICU stay. Ann Pharmacother 2010,44(9),1504-1507","journal-title":"Ann Pharmacother"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"E1860","DOI":"10.3390\/nu12061860","volume":"12","author":"Hong C.T.","year":"2020","unstructured":"Hong C.T.; Chan L.; Bai C.H.; The Effect of Caffeine on the Risk and Progression of Parkinson\u2019s Disease: A Meta-Analysis. Nutrients 2020,12(6),E1860","journal-title":"Nutrients"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s11064-018-2492-0","volume":"44","author":"Camandola S.","year":"2019","unstructured":"Camandola S.; Plick N.; Mattson M.P.; Impact of Coffee and Cacao Purine Metabolites on Neuroplasticity and Neurodegenerative Dis-ease. Neurochem Res 2019,44(1),214-227","journal-title":"Neurochem Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"14741","DOI":"10.1523\/JNEUROSCI.3728-09.2009","volume":"29","author":"Canas P.M.","year":"2009","unstructured":"Canas P.M.; Porci&#xFA;ncula L.O.; Cunha G.M.; Silva C.G.; Machado N.J.; Oliveira J.M.; Oliveira C.R.; Cunha R.A.; Adenosine A2A re-ceptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein ki-nase pathway. J Neurosci 2009,29(47),14741-14751","journal-title":"J Neurosci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/mp.2012.8","volume":"18","author":"Batalha V.L.","year":"2013","unstructured":"Batalha V.L.; Pego J.M.; Fontinha B.M.; Costenla A.R.; Valadas J.S.; Baqi Y.; Radjainia H.; M&#xFC;ller C.E.; Sebasti&#xE3;o A.M.; Lopes L.V.; Adenosine A(2A) receptor blockade reverts hippocampal stress-induced deficits and restores corticosterone circadian oscillation. Mol Psychiatry 2013,18(3),320-331","journal-title":"Mol Psychiatry"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1212\/WNL.25.8.722","volume":"25","author":"Shoulson I.","year":"1975","unstructured":"Shoulson I.; Chase T.; Caffeine and the antiparkinsonian response to levodopa or piribedil. Neurology 1975,25(8),722-724","journal-title":"Neurology"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1002\/mds.26459","volume":"30","author":"Nicoletti A.","year":"2015","unstructured":"Nicoletti A.; Zappia M.; Group F.S.; Coffee consumption and risk of levodopa-induced dyskinesia in Parkinson\u2019s disease: The FRAGAMP study. Mov Disord 2015,30(13),1854-1856","journal-title":"Mov Disord"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/mds.25319","volume":"28","author":"Wills A.M.","year":"2013","unstructured":"Wills A.M.; Eberly S.; Tennis M.; Lang A.E.; Messing S.; Togasaki D.; Tanner C.M.; Kamp C.; Chen J.F.; Oakes D.; McDermott M.P.; Schwarzschild M.A.; Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord 2013,28(3),380-383","journal-title":"Mov Disord"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1212\/01.wnl.0000233916.57415.9d","volume":"67","author":"Deleu D.","year":"2006","unstructured":"Deleu D.; Jacob P.; Chand P.; Sarre S.; Colwell A.; Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkin-son disease. Neurology 2006,67(5),897-899","journal-title":"Neurology"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41598-017-16790-8","volume":"8","author":"Yu Q.J.","year":"2018","unstructured":"Yu Q.J.; Yu S.Y.; Zuo L.J.; Lian T.H.; Hu Y.; Wang R.D.; Piao Y.S.; Guo P.; Liu L.; Jin Z.; Li L.X.; Chan P.; Chen S.D.; Wang X.M.; Zhang W.; Parkinson disease with constipation: clinical features and relevant factors. Sci Rep 2018,8(1),567","journal-title":"Sci Rep"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.euroneuro.2005.01.006","volume":"15","author":"Fernandez N.","year":"2005","unstructured":"Fernandez N.; Carriedo D.; Sierra M.; Diez M.J.; Sahagun A.; Calle A.; Gonzalez A.; Garcia J.J.; Hydrosoluble fiber (Plantago ovata husk) and levodopa II: experimental study of the pharmacokinetic interaction in the presence of carbidopa. Eur Neuropsychopharmacol 2005,15(5),505-509","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.euroneuro.2005.01.005","volume":"15","author":"Garcia J.J.","year":"2005","unstructured":"Garcia J.J.; Fernandez N.; Carriedo D.; Diez M.J.; Sahagun A.; Gonzalez A.; Calle A.; Sierra M.; Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. Eur Neuropsychopharmacol 2005,15(5),497-503","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jns.2008.03.007","volume":"271","author":"Diez M.J.","year":"2008","unstructured":"Diez M.J.; Garcia J.J.; Prieto C.; Fernandez N.; Sahagun A.; Sierra M.; The hydrosoluble fiber Plantago ovata husk improves levodopa (with carbidopa) bioavailability after repeated administration. J Neurol Sci 2008,271(1-2),15-20","journal-title":"J Neurol Sci"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1124\/dmd.108.026229","volume":"37","author":"Garc&#xED;a J.J.","year":"2009","unstructured":"Garc&#xED;a J.J.; Fern&#xE1;ndez N.; Calle A.P.; Diez M.J.; Sahag&#xFA;n A.; Sierra M.; Effects of Plantago ovata husk on levodopa (with Carbidopa) bioavailability in rabbits with autonomic gastrointestinal disorders. Drug Metab Dispos 2009,37(7),1434-1442","journal-title":"Drug Metab Dispos"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/1472-6882-14-296","volume":"14","author":"Fernandez-Martinez M.N.","year":"2014","unstructured":"Fernandez-Martinez M.N.; Hernandez-Echevarria L.; Sierra-Vega M.; Diez-Liebana M.J.; Calle-Pardo A.; Carriedo-Ule D.; Sahag&#xFA;n-Prieto A.M.; Anguera-Vila A.; Garcia-Vieitez J.J.; A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters. BMC Complement Altern Med 2014,14,296","journal-title":"BMC Complement Altern Med"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/00002826-199210000-00004","volume":"15","author":"Astarloa R.","year":"1992","unstructured":"Astarloa R.; Mena M.A.; S&#xE1;nchez V.; de la Vega L.; de Y&#xE9;benes J.G.; Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol 1992,15(5),375-380","journal-title":"Clin Neuropharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1517\/17425251003674364","volume":"6","author":"Fernandez N.","year":"2010","unstructured":"Fernandez N.; Garcia J.J.; Diez M.J.; Sahagun A.M.; D&#xED;ez R.; Sierra M.; Effects of dietary factors on levodopa pharmacokinetics. Expert Opin Drug Metab Toxicol 2010,6(5),633-642","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.toxrep.2019.03.006","volume":"6","author":"Nikolova G.","year":"2019","unstructured":"Nikolova G.; Karamalakova Y.; Gadjeva V.; Reducing oxidative toxicity of L-dopa in combination with two different antioxidants: an essential oil isolated from Rosa Damascena Mill., and vitamin C. Toxicol Rep 2019,6,267-271","journal-title":"Toxicol Rep"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/01.wnf.0000150865.21759.bc","volume":"27","author":"Nagayama H.","year":"2004","unstructured":"Nagayama H.; Hamamoto M.; Ueda M.; Nito C.; Yamaguchi H.; Katayama Y.; The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease. Clin Neuropharmacol 2004,27(6),270-273","journal-title":"Clin Neuropharmacol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1001\/jama.1970.03170300072030","volume":"213","author":"Golden R.L.","year":"1970","unstructured":"Golden R.L.; Mortati F.S.; Schroeter G.A.; Levodopa, pyridoxine, and the burning feet syndrome. JAMA 1970,213(4),628","journal-title":"JAMA"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1001\/jama.1972.03200060085023","volume":"220","author":"Yahr M.D.","year":"1972","unstructured":"Yahr M.D.; Duvoisin R.C.; Pyridoxine and levodopa in the treatment of Parkinsonism. JAMA 1972,220(6),861","journal-title":"JAMA"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.1971.03190260040011","volume":"218","author":"Leon A.S.","year":"1971","unstructured":"Leon A.S.; Spiegel H.E.; Thomas G.; Abrams W.B.; Pyridoxine antagonism of levodopa in parkinsonism. JAMA 1971,218(13),1924-1927","journal-title":"JAMA"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1001\/jama.1970.03170100062021","volume":"211","author":"Jameson H.D.","year":"1970","unstructured":"Jameson H.D.; Pyridoxine for levodopa-induced dystonia. JAMA 1970,211(10),1700","journal-title":"JAMA"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1001\/archneur.1974.00490360020005","volume":"30","author":"Mars H.","year":"1974","unstructured":"Mars H.; Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions. Arch Neurol 1974,30(6),444-447","journal-title":"Arch Neurol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1212\/WNL.24.5.431","volume":"24","author":"Fahn S.","year":"1974","unstructured":"Fahn S.; &#x201C;On-off&#x201D; phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intra-muscular pyridoxine. Neurology 1974,24(5),431-441","journal-title":"Neurology"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1001\/jama.1971.03180220084025","volume":"215","author":"Cotzias G.C.","year":"1971","unstructured":"Cotzias G.C.; Papavasiliou P.S.; Blocking the negative effects of pyridoxine on patients receiving levodopa. JAMA 1971,215(9),1504-1505","journal-title":"JAMA"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1056\/NEJM197201062860102","volume":"286","author":"Papavasiliou P.S.","year":"1972","unstructured":"Papavasiliou P.S.; Cotzias G.C.; D&#xFC;by S.E.; Steck A.J.; Fehling C.; Bell M.A.; Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor. N Engl J Med 1972,286(1),8-14","journal-title":"N Engl J Med"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1136\/jnnp.34.6.682","volume":"34","author":"Klawans H.L.","year":"1971","unstructured":"Klawans H.L.; Ringel S.P.; Shenker D.M.; Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibi-tor. J Neurol Neurosurg Psychiatry 1971,34(6),682-686","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/WNF.0000000000000408","volume":"43","author":"Rojo-Sebasti&#xE1;n A.","year":"2020","unstructured":"Rojo-Sebasti&#xE1;n A.; Gonz&#xE1;lez-Robles C.; Garc&#xED;a de Y&#xE9;benes J.; Vitamin B6 deficiency in patients with Parkinson disease treated with levodopa\/carbidopa. Clin Neuropharmacol 2020,43(5),151-157","journal-title":"Clin Neuropharmacol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/mdc3.12688","volume":"6","author":"Romagnolo A.","year":"2018","unstructured":"Romagnolo A.; Merola A.; Artusi C.A.; Rizzone M.G.; Zibetti M.; Lopiano L.; Levodopa-induced neuropathy: a systematic review. Mov Disord Clin Pract (Hoboken) 2018,6(2),96-103","journal-title":"Mov Disord Clin Pract (Hoboken)"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"e00698","DOI":"10.1002\/brb3.698","volume":"7","author":"Loens S.","year":"2017","unstructured":"Loens S.; Chorbadzhieva E.; Kleimann A.; Dressler D.; Schrader C.; Effects of levodopa\/carbidopa intestinal gel versus oral levodo-pa\/carbidopa on B vitamin levels and neuropathy. Brain Behav 2017,7(5),e00698","journal-title":"Brain Behav"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"Li J.","year":"2020","unstructured":"Li J.; Cao F.; Yin H.L.; Huang Z.J.; Lin Z.T.; Mao N.; Sun B.; Wang G.; Ferroptosis: past, present and future. Cell Death Dis 2020,11(2),88","journal-title":"Cell Death Dis"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"101890","DOI":"10.1016\/j.pneurobio.2020.101890","volume":"196","author":"Mahoney-S&#xE1;nchez L.","year":"2021","unstructured":"Mahoney-S&#xE1;nchez L.; Bouchaoui H.; Ayton S.; Devos D.; Duce J.A.; Devedjian J.C.; Ferroptosis and its potential role in the physio-pathology of Parkinson\u2019s Disease. Prog Neurobiol 2021,196,101890","journal-title":"Prog Neurobiol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40266-015-0241-5","volume":"32","author":"Tay H.S.","year":"2015","unstructured":"Tay H.S.; Soiza R.L.; Systematic review and meta-analysis: what is the evidence for oral iron supplementation in treating anaemia in el-derly people? Drugs Aging 2015,32(2),149-158","journal-title":"Drugs Aging"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/clpt.1989.21","volume":"45","author":"Campbell N.R.","year":"1989","unstructured":"Campbell N.R.; Hasinoff B.; Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. Clin Pharmacol Ther 1989,45(3),220-225","journal-title":"Clin Pharmacol Ther"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1365-2125.1990.tb03819.x","volume":"30","author":"Campbell N.R.","year":"1990","unstructured":"Campbell N.R.; Rankine D.; Goodridge A.E.; Hasinoff B.B.; Kara M.; Sinemet-ferrous sulphate interaction in patients with Parkinson\u2019s disease. Br J Clin Pharmacol 1990,30(4),599-605","journal-title":"Br J Clin Pharmacol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"171492","DOI":"10.1098\/rsos.171492","volume":"5","author":"Zhang Q.","year":"2018","unstructured":"Zhang Q.; Jin B.; Wang X.; Lei S.; Shi Z.; Zhao J.; Liu Q.; Peng R.; The mono(catecholamine) derivatives as iron chelators: synthesis, solution thermodynamic stability and antioxidant properties research. R Soc Open Sci 2018,5(6),171492","journal-title":"R Soc Open Sci"},{"key":"ref=89","unstructured":"Feraccru (Norgine B.V.) Product characteristics. Available from:  (accessed Apr 30, 2021)."},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1212\/WNL.43.3_Part_1.611","volume":"43","author":"Karstaedt P.J.","year":"1993","unstructured":"Karstaedt P.J.; Pincus J.H.; Aspartame use in Parkinson\u2019s disease. Neurology 1993,43(3 Pt 1),611-613","journal-title":"Neurology"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/(SICI)1099-081X(199607)17:5<443::AID-BDD443>3.0.CO;2-U","volume":"17","author":"Persiani S.","year":"1996","unstructured":"Persiani S.; Rocchetti M.; Pacciarini M.A.; Holt B.; Toon S.; Strolin-Benedetti M.; The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. Biopharm Drug Dispos 1996,17(5),443-455","journal-title":"Biopharm Drug Dispos"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1046\/j.1365-2125.1998.t01-1-00704.x","volume":"45","author":"Brefel C.","year":"1998","unstructured":"Brefel C.; Thalamas C.; Rayet S.; Lopez-Gil A.; Fitzpatrick K.; Bullman S.; Citerone D.R.; Taylor A.C.; Montastruc J.L.; Rascol O.; Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. Br J Clin Pharmacol 1998,45(4),412-415","journal-title":"Br J Clin Pharmacol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1016\/j.clinthera.2007.12.010","volume":"29","author":"Tompson D.J.","year":"2007","unstructured":"Tompson D.J.; Vearer D.; Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson\u2019s disease. Clin Ther 2007,29(12),2654-2666","journal-title":"Clin Ther"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1365-2710.2012.01336.x","volume":"37","author":"Hattori N.","year":"2012","unstructured":"Hattori N.; Hasegawa K.; Sakamoto T.; Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson\u2019s disease. J Clin Pharm Ther 2012,37(5),571-577","journal-title":"J Clin Pharm Ther"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/BF00558250","volume":"35","author":"Drewe J.","year":"1988","unstructured":"Drewe J.; Mazer N.; Abisch E.; Krummen K.; Keck M.; Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation. Eur J Clin Pharmacol 1988,35(5),535-541","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/BF03189956","volume":"16","author":"Kopitar Z.","year":"1991","unstructured":"Kopitar Z.; Vrhovac B.; Povsic L.; Plavsi\u0107 F.; Franceti\u0107 I.; Urbancic, J. The effect of food and metoclopramide on the pharmacokinetics and side effects of bromocriptine. Eur J Drug Metab Pharmacokinet 1991,16(3),177-181","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=97","unstructured":"Parlodel&#xAE; (Novartis). Prescribing information. Available from:  (accessed 30 Apr, 2021)."},{"key":"ref=98","unstructured":"REQUIP&#xAE; (GSK). Prescribing information. Available from:  (accessed 30 Apr, 2021)."},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1074\/jbc.M111.317081","volume":"287","author":"Sevrioukova I.F.","year":"2012","unstructured":"Sevrioukova I.F.; Poulos T.L.; Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand. J Biol Chem 2012,287(5),3510-3517","journal-title":"J Biol Chem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40263-019-00646-y","volume":"33","author":"Frampton J.E.","year":"2019","unstructured":"Frampton J.E.; Rotigotine transdermal patch: A review in Parkinson\u2019s disease. CNS Drugs 2019,33(7),707-718","journal-title":"CNS Drugs"},{"key":"ref=101","unstructured":"Tasmar (Valeant) Prescribing information Available from:  (accessed Apr 30, 2021).","journal-title":"Prescribing information"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1046\/j.1365-2125.2000.00113.x","volume":"49","author":"Jorga K.","year":"2000","unstructured":"Jorga K.; Fotteler B.; Banken L.; Snell P.; Steimer J.L.; Population pharmacokinetics of tolcapone in parkinsonian patients in dose find-ing studies. Br J Clin Pharmacol 2000,49(1),39-48","journal-title":"Br J Clin Pharmacol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40262-012-0024-7","volume":"52","author":"Almeida L.","year":"2013","unstructured":"Almeida L.; Rocha J.F.; Falc&#xE3;o A.; Palma P.N.; Loureiro A.I.; Pinto R.; Bonif&#xE1;cio M.J.; Wright L.C.; Nunes T.; Soares-da-Silva P.; Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet 2013,52(2),139-151","journal-title":"Clin Pharmacokinet"},{"key":"ref=104","first-page":"S123","volume":"2017","author":"Santos A.F.","year":"2017","unstructured":"Santos A.F.; Ferreira J.; Lees A.; Hernandez B.; Rocha F.; Soares-da-Silva P.; Effect of food on Opicapone pharmacokinetics and pharmacodynamics. Eur J Neurol 2017,2017(24),S123-S444","journal-title":"Eur J Neurol"},{"key":"ref=105","unstructured":"Ongentys (Neurocrine Biosciences) Prescribing information Available from:  (accessed May 14, 2021).","journal-title":"Prescribing information"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.4088\/JCP.11096tx6c","volume":"73","author":"Vandenberg C.M.","year":"2012","unstructured":"Vandenberg C.M.; MAOIs and transdermal delivery. J Clin Psychiatry 2012,73(9),e28","journal-title":"J Clin Psychiatry"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/00045391-199604000-00008","volume":"3","author":"Barrett J.S.","year":"1996","unstructured":"Barrett J.S.; Rohatagi S.; DeWitt K.E.; Morales R.J.; DiSanto A.R.; The effect of dosing regimen and food on the bioavailability of the extensively metabolized, highly variable drug eldepryl&#xAE; (selegiline hydrochloride). Am J Ther 1996,3(4),298-313","journal-title":"Am J Ther"},{"key":"ref=108","unstructured":"Eldepryl (Orion Pharma) Product characteristics. Available from:  (accessed May 17, 2021)."},{"key":"ref=109","unstructured":"Zelapar (Valeant) Prescribing information Available from: (accessed May 14, 2021).","journal-title":"Prescribing information"},{"key":"ref=110","first-page":"85","volume":"44","author":"Gu X.","year":"2013","unstructured":"Gu X.; Zhang Y.; Song M.; Hang T.; Yang L.; Wen A.; Food effects on the human pharmacokinetics of rasagiline mesylate. Zhongguo Yaoke Daxue Xuebao 2013,44,85-88","journal-title":"Zhongguo Yaoke Daxue Xuebao"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"571747","DOI":"10.3389\/fphar.2020.571747","volume":"11","author":"Li Y.","year":"2020","unstructured":"Li Y.; Qi L.; Bai H.; Liu Y.; Fan R.; Tu Y.; Sun Y.; Wang J.; Qi Q.; Feng X.; Zhou D.; Wang X.; Pharmacokinetics and Bioequiva-lence of Rasagiline Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions: An Open, Randomized, Single-Dose, Double-Cycle, Two-Sequence. Crossover Trial Front Pharmacol 2020,11,571747","journal-title":"Crossover Trial Front Pharmacol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.phrs.2003.12.004","volume":"50","author":"Marzo A.","year":"2004","unstructured":"Marzo A.; Dal Bo L.; Monti N.C.; Crivelli F.; Ismaili S.; Caccia C.; Cattaneo C.; Fariello R.G.; Pharmacokinetics and pharmacodynam-ics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res 2004,50(1),77-85","journal-title":"Pharmacol Res"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/cpdd.2","volume":"2","author":"Seithel-Keuth A.","year":"2013","unstructured":"Seithel-Keuth A.; Johne A.; Freisleben A.; Kupas K.; Lissy M.; Kr&#xF6;sser S.; Absolute Bioavailability and Effect of Food on the Disposi-tion of Safinamide Immediate Release Tablets in Healthy Adult Subjects. Clin Pharmacol Drug Dev 2013,2(1),79-89","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/nutrit\/nuy036","volume":"77","author":"Andersen G.","year":"2019","unstructured":"Andersen G.; Marcinek P.; Sulzinger N.; Schieberle P.; Krautwurst D.; Food sources and biomolecular targets of tyramine. Nutr Rev 2019,77(2),107-115","journal-title":"Nutr Rev"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3181\/00379727-143-37370","volume":"143","author":"Hsu T.H.","year":"1973","unstructured":"Hsu T.H.; Bianchine J.R.; Preziosi T.J.; Messiha F.S.; Effect of pyridoxine on levodopa metabolism in normal and parkinsonian sub-jects. Proc Soc Exp Biol Med 1973,143(2),578-581","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/B978-0-12-386467-3.00009-1","volume":"100","author":"Finberg J.P.","year":"2011","unstructured":"Finberg J.P.; Gillman K.; Selective inhibitors of monoamine oxidase type B and the &#x201C;cheese effect&#x201D;. Int Rev Neurobiol 2011,100,169-190","journal-title":"Int Rev Neurobiol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1365-2125.2010.03777.x","volume":"70","author":"Haffner S.K.M.","year":"2010","unstructured":"Haffner S.K.M.; Reseski K.; Greiling D.; Jones P.S.; Fuder H.; Supratherapeutic doses of EVT 302, a new selective MAO-B inhibitor, do not produce clinically significant increases in tyramine induced blood pressure rise in healthy male subjects. Br J Clin Pharmacol 2010,70,8","journal-title":"Br J Clin Pharmacol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF00426954","volume":"57","author":"Elsworth J.D.","year":"1978","unstructured":"Elsworth J.D.; Glover V.; Reynolds G.P.; Sandler M.; Lees A.J.; Phuapradit P.; Shaw K.M.; Stern G.M.; Kumar P.; Deprenyl admin-istration in man: a selective monoamine oxidase B inhibitor without the \u2018cheese effect\u2019. Psychopharmacology (Berl) 1978,57(1),33-38","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF01246961","volume":"43","author":"Stern G.M.","year":"1978","unstructured":"Stern G.M.; Lees A.J.; Sandler M.; Recent observations on the clinical pharmacology of (-)deprenyl. J Neural Transm (Vienna) 1978,43(3-4),245-251","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1177\/0091270010369674","volume":"50","author":"Goren T.","year":"2010","unstructured":"Goren T.; Adar L.; Sasson N.; Weiss Y.M.; Clinical pharmacology tyramine challenge study to determine the selectivity of the monoam-ine oxidase type B (MAO-B) inhibitor rasagiline. J Clin Pharmacol 2010,50(12),1420-1428","journal-title":"J Clin Pharmacol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/clpt.2012.128","volume":"92","author":"Marquet A.","year":"2012","unstructured":"Marquet A.; Kupas K.; Johne A.; Astruc B.; Patat A.; Kr&#xF6;sser S.; Kovar A.; The effect of safinamide, a novel drug for Parkinson\u2019s disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. Clin Pharmacol Ther 2012,92(4),450-457","journal-title":"Clin Pharmacol Ther"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1002\/mds.21048","volume":"21","author":"deMarcaida J.A.","year":"2006","unstructured":"deMarcaida J.A.; Schwid S.R.; White W.B.; Blindauer K.; Fahn S.; Kieburtz K.; Stern M.; Shoulson I.; Effects of tyramine administra-tion in Parkinson\u2019s disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 2006,21(10),1716-1721","journal-title":"Mov Disord"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/clpt.1989.181","volume":"46","author":"Schulz R.","year":"1989","unstructured":"Schulz R.; Antonin K.H.; Hoffmann E.; Jedrychowski M.; Nilsson E.; Schick C.; Bieck P.R.; Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther 1989,46(5),528-536","journal-title":"Clin Pharmacol Ther"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/00131746-200605000-00006","volume":"12","author":"Preskorn S.H.","year":"2006","unstructured":"Preskorn S.H.; Why the transdermal delivery of selegiline (6 mg\/24 hr) obviates the need for a dietary restriction on tyramine. J Psychiatr Pract 2006,12(3),168-172","journal-title":"J Psychiatr Pract"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/BF00172970","volume":"95","author":"Prasad A.","year":"1988","unstructured":"Prasad A.; Glover V.; Goodwin B.L.; Sandler M.; Signy M.; Smith S.E.; Enhanced pressor sensitivity to oral tyramine challenge follow-ing high dose selegiline treatment. Psychopharmacology (Berl) 1988,95(4),540-543","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=126","first-page":"63","volume":"25","author":"McGrath P.J.","year":"1989","unstructured":"McGrath P.J.; Stewart J.W.; Harrison W.; Wager S.; Nunes E.N.; Quitkin F.M.; A placebo-controlled trial of L-deprenyl in atypical de-pression. Psychopharmacol Bull 1989,25(1),63-67","journal-title":"Psychopharmacol Bull"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00210-011-0674-2","volume":"384","author":"Di Stefano A.F.","year":"2011","unstructured":"Di Stefano A.F.; Rusca A.; Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol 2011,384(6),505-515","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.gerinurse.2006.10.015","volume":"27","author":"Zarowitz B.J.","year":"2006","unstructured":"Zarowitz B.J.; Oral solid potassium chloride and anticholinergic medications: a new drug interaction for an old drug? Geriatr Nurs 2006,27(6),329-333","journal-title":"Geriatr Nurs"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1111\/bcp.14616","volume":"87","author":"Gueta I.","year":"2021","unstructured":"Gueta I.; Markovits N.; Halkin H.; Loebstein R.; Concomitant oral potassium chloride and anticholinergic therapy is associated with upper gastrointestinal bleeding: A cohort study. Br J Clin Pharmacol 2021,87(4),2064-2069","journal-title":"Br J Clin Pharmacol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2147\/TCRM.S144481","volume":"14","author":"Sharma V.D.","year":"2018","unstructured":"Sharma V.D.; Lyons K.E.; Pahwa R.; Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkin-son\u2019s disease. Ther Clin Risk Manag 2018,14,665-673","journal-title":"Ther Clin Risk Manag"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40120-019-0144-1","volume":"8","author":"deVries T.","year":"2019","unstructured":"deVries T.; Dentiste A.; Handiwala L.; Jacobs D.; Bioavailability and pharmacokinetics of once-daily amantadine extended-release tab-lets in healthy volunteers: results from three randomized, crossover, open-label, phase 1 studies. Neurol Ther 2019,8(2),449-460","journal-title":"Neurol Ther"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1177\/0091270007299361","volume":"47","author":"Vanover K.E.","year":"2007","unstructured":"Vanover K.E.; Robbins-Weilert D.; Wilbraham D.G.; Mant T.G.; van Kammen D.P.; Davis R.E.; Weiner D.M.; The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers. J Clin Pharmacol 2007,47(7),915-919","journal-title":"J Clin Pharmacol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00702-003-0042-6","volume":"110","author":"Clarke A.","year":"2003","unstructured":"Clarke A.; Johnson E.S.; Mallard N.; Corn T.H.; Johnston A.; Boyce M.; Warrington S.; MacMahon D.G.; A new low-dose formula-tion of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm (Vienna) 2003,110(11),1257-1271","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=134","first-page":"340","volume":"19","author":"Simpson G.W.K.","year":"1983","unstructured":"Simpson G.W.K.; Pi E.; Razani J.; Sloane R.B.; Monoamine oxidase inhibition and tyramine sensitivity in L -deprenyl-treated subjects. Psychopharmacol Bull 1983,19,340-342","journal-title":"Psychopharmacol Bull"},{"key":"ref=135","first-page":"517","volume":"115","author":"Durakovic Z.V.D.","year":"2013","unstructured":"Durakovic Z.V.D.; Pharmacodynamics and pharmacokinetics in the elderly. Period Biol 2013,115,517-520","journal-title":"Period Biol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.mpmed.2016.10.008","volume":"45","author":"Navaratnarajah A.","year":"2017","unstructured":"Navaratnarajah A.; Jackson S.H.D.; The physiology of ageing. Medicine (Baltimore) 2017,45,6-10","journal-title":"Medicine (Baltimore)"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X19666211116142806","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/197964\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X19666211116142806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T11:51:28Z","timestamp":1659441088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/197964\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":136,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x19666211116142806","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}